JPMorgan Chase & Co. reissued their overweight rating on shares of Shire PLC (LON:SHP) in a report released on Tuesday morning. The brokerage currently has a GBX 6,000 ($74.10) price objective on the biopharmaceutical company’s stock.
SHP has been the subject of several other research reports. Deutsche Bank AG reissued a buy rating on shares of Shire PLC in a report on Tuesday, January 3rd. Liberum Capital reissued a buy rating and set a GBX 5,500 ($67.93) target price on shares of Shire PLC in a report on Thursday, December 22nd. Jefferies Group LLC reissued a buy rating and set a GBX 6,600 ($81.51) target price on shares of Shire PLC in a report on Friday, February 17th. Royal Bank of Canada reissued an outperform rating on shares of Shire PLC in a report on Monday, March 20th. Finally, Citigroup Inc reissued a buy rating on shares of Shire PLC in a report on Friday, February 17th. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of GBX 6,115.60 ($75.53).
Shire PLC (LON:SHP) opened at 4685.00 on Tuesday. The company’s market cap is GBX 42.29 billion. The firm’s 50 day moving average is GBX 4,761.49 and its 200 day moving average is GBX 4,764.24. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00.
The business also recently announced a dividend, which will be paid on Tuesday, April 25th. Stockholders of record on Thursday, March 9th will be given a GBX 20.64 ($0.25) dividend. This is a positive change from Shire PLC’s previous dividend of $3.51. The ex-dividend date is Thursday, March 9th. This represents a dividend yield of 0.43%.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.